Difference between revisions of "Pemmaraju N, et al. Blood (2016) cited as Ref 558 in DOI: 10.1038/s41392-020-0110-5 (Q9821)"
Jump to navigation
Jump to search
(Created claim: title (P93): Results from phase 2 trial ongoing expansion stage of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), #quickstatements; #temporary_batch_1590010982689) |
(Created claim: Page(s) (P105): 342-342, #quickstatements; #temporary_batch_1590074839150) |
||
| Property / Page(s) | |||
| + | 342-342 | ||
| Property / Page(s): 342-342 / rank | |||
| + | Normal rank | ||
Latest revision as of 15:45, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Pemmaraju N, et al. Blood (2016) cited as Ref 558 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Pemmaraju N
0 references
2016
0 references
Blood
0 references
128
0 references
Results from phase 2 trial ongoing expansion stage of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) (English)
0 references
342-342
0 references
